UK's NICE opens consultation on drug assessments and recommendations

27 March 2014
nhs-big

The UK’s National Institute for Health and Care Excellence (NICE) is beginning a formal consultation on proposed changes to the way it makes recommendations on new medicines and other treatments for use in the National Health System (NHS).

NICE assesses the clinical and cost effectiveness of new technologies to help ensure that patients have access to effective treatments and the NHS makes the best use of its resources. It says the new proposals include ways to take into account “more systematically and explicitly the severity of a disease”.

NICE chief executive Sir Andrew Dillon said: “These proposed changes to the way we value new treatments will add further clarity to our recommendations and enable our independent advisory committees to explore more fully the potential these treatments have to improve outcomes for patients.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical